Allergan's Ganfort beats Xalacom in trial
California, USA-based Allergan reported data from a study which claims its Ganfort (bimatoprost/timolol) drug provided greater benefit in treating intra-ocular pressure in glaucoma patients than Pfizer's Xalacom (latanoprost), at the European Glaucoma Society in Berlin, Germany.
The study in 54 patients with open-angle glaucoma found that Ganfort provided significantly greater reduction in IOP after 12 weeks of treatment compared to Xalacom. Lowering IOP is the only proven means for preserving patients' visual field.
The trial also showed that Ganfort stabilizes fluctutations in IOP over the course of 24 hours. Varying IOP is as dangerous as high, according to the company.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze